New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 23, 2012
13:15 EDTALU, RIMM, OCZ, BAX, MAPP, WMTOn The Fly: Closing Wrap
Stocks on Wall Street were higher during the post-holiday short session, with each of the major averages adding over 1%. Following an initial move higher in the first hour after the bell, aided by some encouraging economic data from abroad, the indices drifted higher for the remainder of the day and closed at their highs... ECONOMIC EVENTS: In the U.S., no major economic data was released, however, in Europe, separate reports showed business confidence increased in November in both Germany and France. Also, in China, HSBC's Manufacturing Purchasing Managers' Index increased to 50.4, indicating expansion... COMPANY NEWS: Wal-Mart (WMT) announced had its "best ever Black Friday events" in spite of some scattered strikes by workers and shares advanced $1.31, or 1.90%, to $70.20... Research in Motion (RIMM) shares benefited a day after National Bank raised it price target on the stock to $15 from $12. The firm said in a note to investors yesterday that RIM's new management team is executing by maintaining the BlackBerry subscriber base and U.S. listed shares rose $1.40, or 13.65%, to $11.66 in their first day of trading following the bullish write-up... Shares of Baxter (BAX) moved up $2.69, or 4.07%, to $68.81 after The Wall Street Journal said the company is in talks to buy medical-equipment maker Gambro for about $4B to round out its kidney-dialysis business... MAJOR MOVERS: Among the notable gainers were Alcatel-Lucent (ALU), up 10c, or 10.00%, to $1.10 after Bloomberg said the company is in talks with Goldman Sachs (GS) on a loan to strengthen its balance sheet, and MAP Pharmaceuticals (MAPP), up $2.60, or 20.28%, to $15.42 after the company announced that the FDA accepted its Levadex resubmission with a six-month review. Among the noteworthy losers was OCZ Technology (OCZ), which fell 3c, or 2.52%, to $1.16 following its disclosure of a SEC inquiry... INDICES: The Dow was up 172.79, or 1.35%, to 13,009.68; the Nasdaq was up 40.30, or 1.38%, to 2,966.85; and the S&P 500 was up 18.12, or 1.30%, to 1,409.15.
News For RIMM;WMT;BAX;ALU;MAPP;OCZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:17 EDTBAXSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 22, 2015
11:32 EDTALUF5 Networks plummets after Q2 outlook trails estimates
Subscribe for More Information
10:03 EDTALUOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Buy from Neutral at Nomura... Alcatel-Lucent (ALU) upgraded to Conviction Buy from Neutral at Goldman... Chuy's (CHUY) upgraded at Wells Fargo... Coty (COTY) upgraded to Buy from Neutral at Citigroup... Era Group (ERA) upgraded to Buy from Hold at Evercore ISI... Exterran (EXH) upgraded to Buy from Hold at Evercore ISI... F5 Networks (FFIV) upgraded to Buy from Neutral at Buckingham... Joy Global (JOY) upgraded to Outperform from Market Perform at BMO Capital... Lennox (LII) upgraded to Buy from Neutral at UBS... RSA Insurance (RSNAY) upgraded to Outperform from Neutral at Credit Suisse... Rockwell Automation (ROK) upgraded to Buy from Neutral at UBS... SodaStream (SODA) upgraded to Hold from Sell at Stifel... eBay (EBAY) upgraded to Equal Weight from Underweight at Morgan Stanley.
05:45 EDTALUAlcatel-Lucent upgraded to Conviction Buy from Neutral at Goldman
January 21, 2015
13:38 EDTWMTEarnings Preview: eBay shares rise over 5.5% since last earnings report
Subscribe for More Information
10:01 EDTWMTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:52 EDTWMTWal-Mart downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Wal-Mart to Equal Weight citing balanced risk/reward and lack of margin growth due to potential re-investments.
January 20, 2015
13:01 EDTWMTWal-Mart launches cash pickup option for tax refunds
As Americans begin to file their tax returns, Walmart (WMT) announced the launch of a first-of-its-kind service that allows consumers to “skip the check” and pick up their tax refunds in cash. Walmart Direct2Cash is available nationwide starting today and will help customers save time and money when compared to traditional tax refund options. Walmart is working with Tax Products Group, a Green Dot Company (GDOT), and Republic Bank & Trust Company, member FDIC, two providers of tax-related financial products and services, to provide Walmart Direct2Cash as an option to millions of customers. The more than 25,000 tax preparation locations using software with the Walmart Direct2Cash option may provide this service for no additional fee or charge a maximum of $7 at the time of filing. Walmart does not charge customers a fee when refunds are claimed in a store.
09:44 EDTWMTSupreme Court denies appeal of 'swipe fee' ruling, Reuters reports
Subscribe for More Information
09:02 EDTBAXBaxter receives FDA approval for PHOXILLUM solution
Subscribe for More Information
08:16 EDTBAXMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
January 16, 2015
10:12 EDTWMTSprint unit Virgin Mobile to offer no contract data sharing plans
Subscribe for More Information
January 15, 2015
13:07 EDTALUNetworking trends seen as boon for Cisco, others
Subscribe for More Information
09:24 EDTWMTEpiq Systems to hold a webinar
Subscribe for More Information
07:02 EDTALUTrends positive for data networking names, says Bernstein
Subscribe for More Information
January 14, 2015
16:00 EDTWMTOptions Update; January 14, 2015
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use